Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cisplatin
Phase I finding of capecitabine (Xeloda), radiotherapy and cisplatin revealed
September 15th, 2005
Scientists revealed the phase I maximum tolerated dose (MTD) finding of capecitabine (Xeloda), radiotherapy, and cisplatin. According to a study from United Kingdom, "A dose escalation study was performed for patients with locally advanced squamous carcinoma of cervix to determine the MTD of daily capecitabine when combined with weekly cisplatin and radiotherapy. MTD would be reached if at least 2 out of 6 at any particular dose level developed Grade 3 or 4 diarrhea, mucositis, skin or bladder toxicity or Grade 4 neutropenia associated with fever lasting more than 7 days or Grade 3 or 4 thrombocytopenia." "The secondary endpoints were to define the...
Source: Women's Health Weekly (2005-09-15)
|
